Nevanac is a drug owned by Harrow Eye Llc. It is protected by 4 US drug patents filed in 2013. Out of these, 3 drug patents are active and 1 has expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 31, 2027. Details of Nevanac's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US7834059 | Topical nepafenac formulations |
Jan, 2027
(1 year, 8 months from now) | Active |
| US8071648 | Topical nepafenac formulations |
Dec, 2025
(6 months from now) | Active |
| US8324281 | Topical nepafenac formulations |
Dec, 2025
(6 months from now) | Active |
| US5475034 | Topically administrable compositions containing 3-benzoylphenylacetic acid derivatives for treatment of ophthalmic inflammatory disorders |
Jun, 2014
(10 years ago) |
Expired
|
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Nevanac's patents.
Latest Legal Activities on Nevanac's Patents
Given below is the list of recent legal activities going on the following patents of Nevanac.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 17 Dec, 2023 | US8324281 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 04 Dec, 2023 | US8324281 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 Mar, 2023 | US7834059 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 Mar, 2023 | US8071648 |
| Email Notification Critical | 07 Mar, 2023 | US8324281 |
| Email Notification Critical | 07 Mar, 2023 | US8071648 |
| Change in Power of Attorney (May Include Associate POA) Critical | 07 Mar, 2023 | US8324281 |
| Email Notification Critical | 07 Mar, 2023 | US7834059 |
| Payment of Maintenance Fee, 12th Yr, Small Entity | 02 Mar, 2023 | US8071648 |
| Applicant Has Filed a Verified Statement of Small Entity Status in Compliance with 37 CFR 1.27 | 02 Mar, 2023 | US8071648 |
US patents provide insights into the exclusivity only within the United States, but Nevanac is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Nevanac's family patents as well as insights into ongoing legal events on those patents.
Nevanac's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Nevanac's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 31, 2027 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Nevanac Generics:
There are no approved generic versions for Nevanac as of now.
Alternative Brands for Nevanac
Nevanac which is used for treating ocular inflammation., has several other brand drugs in the same treatment category and using the same active ingredient (Nepafenac). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
About Nevanac
Nevanac is a drug owned by Harrow Eye Llc. It is used for treating ocular inflammation. Nevanac uses Nepafenac as an active ingredient. Nevanac was launched by Harrow Eye in 2005.
Approval Date:
Nevanac was approved by FDA for market use on 19 August, 2005.
Active Ingredient:
Nevanac uses Nepafenac as the active ingredient. Check out other Drugs and Companies using Nepafenac ingredient
Treatment:
Nevanac is used for treating ocular inflammation.
Dosage:
Nevanac is available in suspension/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | SUSPENSION/DROPS | Prescription | OPHTHALMIC |